DDInter1592 DDInter481
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Abiraterone
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nefazodone
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Miconazole
Miconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Darolutamide
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound) and Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Rifapentine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide